Contact
One of the most prestigious biotech and health websites, Fierce Biotech Research, reports on the discovery made by Antonio Zorzano’s group at IRB Barcelona. Published in PNAS, the study addresses the validation of Mitofusin 2 as a posible therapeutic target for type 2 diabetes.
Read the news Fierce Biotech Research (PDF)
Link to Fierce Biotech Research
Link to the IRB Barcelona news
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
